Evidence map›Paper›PMID 19593408›Full record

ArticleMolecular medicine (Cambridge, Mass.)

The immunohistochemical expression of growth hormone-releasing hormone receptor splice variant 1 is a favorable prognostic marker in colorectal cancer.

Elena Theophanous, Constantina Petraki, Andreas Scorilas, Vassilios Komborozos, George Veloudis, Jozsef L Varga, Marta Zarandi, Andrew V Schally, Michael Koutsilieris

Open access · goldAbstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. GHRH and the prostate.Reviews in endocrine & metabolic disorders · 2025
    Review
  2. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling.Reviews in endocrine & metabolic disorders · 2025
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Elena TheophanousDepartment of Pathology, Evangelismos Hospital, Athens, Greece.
Constantina Petraki
Andreas Scorilas
Vassilios Komborozos
George Veloudis
Jozsef L Varga
Marta Zarandi
Andrew V Schally
Michael Koutsilieris
Evangelismos Hospital · GRSouth Florida Veterans Affairs Foundation for Research and Education · USNational and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypothalamic growth hormone (GH)-releasing hormone (GHRH) regulates the release of GH from the pituitary gland. The receptors for GHRH (GHRH-R) are expressed predominantly in the pituitary. Recent evidence demonstrates that splice variants of the GHRH receptor are also expressed in several nonpituitary tissues, both normal and tumoral, as well as in cancer cell lines. The aim of this study was to investigate the expression of the splice variant 1 (SV-1) of GHRH-R in colorectal cancer (CRC). Seventy patients who underwent partial colectomy for CRC were enrolled in the study. Immunohistochemical expression of SV-1 was studied in paraffin-embedded sections of patient tumor tissue. A cytoplasmic supranuclear expression of SV-1 was observed in CRC as well as in the normal colon mucosa. Tumor grade and pathological stage were negatively correlated with expression of SV-1 (P = 0.012 and P = 0.013, respectively). CRCs metastatic to the liver showed a lower expression of SV-1 than did primary tumors, but this difference was not statistically significant. Kaplan-Meier and Cox univariate survival analyses indicated an improved survival time in patients with high SV-1 compared with those with low GHRH-R expression, but this difference was not statistically significant. The immunohistochemical expression of SV-1 seems to be a favorable prognostic factor in CRC.

Indexed as

AdultAgedAged, 80 and overAxin ProteinBiomarkers, TumorCadherinsCohort StudiesColorectal NeoplasmsCytoskeletal ProteinsFemaleHumansImmunohistochemistryKaplan-Meier EstimateMaleMiddle AgedNeoplasm InvasivenessAXIN2 protein, humanAxin ProteinBiomarkers, TumorCadherinsCytoskeletal ProteinsProtein IsoformsReceptors, NeuropeptideReceptors, Pituitary Hormone-Regulating Hormonesomatotropin releasing hormone receptor

Identifiers

PMID19593408
PMCPMC2707517
OpenAlexW2346856159

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.